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There is increasing evidence that brain-derived neurotrophic factor (BDNF) plays a
crucial role in Alzheimer’s disease (AD) pathology. A number of studies demonstrated
that AD patients exhibit reduced BDNF levels in the brain and the blood serum,
and in addition, several animal-based studies indicated a potential protective effect
of BDNF against Aβ-induced neurotoxicity. In order to further investigate the role
of BDNF in the etiology of AD, we created a novel mouse model by crossing
a well-established AD mouse model (APP/PS1) with a mouse exhibiting a chronic
BDNF deficiency (BDNF+/−). This new triple transgenic mouse model enabled us to
further analyze the role of BDNF in AD in vivo. We reasoned that in case BDNF
has a protective effect against AD pathology, an AD-like phenotype in our new
mouse model should occur earlier and/or in more severity than in the APP/PS1-
mice. Indeed, the behavioral analysis revealed that the APP/PS1-BDNF+/−-mice show
an earlier onset of learning impairments in a two-way active avoidance task in
comparison to APP/PS1- and BDNF+/−-mice. However in the Morris water maze
(MWM) test, we could not observe an overall aggrevated impairment in spatial
learning and also short-term memory in an object recognition task remained intact
in all tested mouse lines. In addition to the behavioral experiments, we analyzed
the amyloid plaque pathology in the APP/PS1 and APP/PS1-BDNF+/−-mice and
observed a comparable plaque density in the two genotypes. Moreover, our results
revealed a higher plaque density in prefrontal cortical compared to hippocampal
brain regions. Our data reveal that higher cognitive tasks requiring the recruitment of
cortical networks appear to be more severely affected in our new mouse model than
learning tasks requiring mainly sub-cortical networks. Furthermore, our observations
of an accelerated impairment in active avoidance learning in APP/PS1-BDNF+/−-mice
further supports the hypothesis that BDNF deficiency amplifies AD-related cognitive
dysfunctions.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia (Kawas and Corrada, 2006), resulting in a progressive
decline of cognitive functions (Blennow et al., 2006). While
the cellular and molecular mechanisms that underlie AD are
still not well understood, some neuropathological hallmarks
were already identified. These include neurofibrillary tangles
consisting of aggregated hyperphosphorylated tau protein and
neuritic plaques characterized by an overload of mainly insoluble
Aβ peptides (e.g., Hardy and Higgins, 1992). Mutations in the
amyloid precursor protein (APP) and the presenilin genes (PS1
and PS2), which are both linked to the familiar form of AD (e.g.,
Goate et al., 1991), have been described to lead to a massive
increase in cytotoxic Aβ40 and Aβ42 oligomers (e.g., Walker et al.,
2005; Theuns et al., 2006).
One of the main objectives of Alzheimer research is to identify
novel therapeutic approaches alleviating cognitive deficits. In
this context, focusing on neurotrophin signaling appears to
be a promising approach. Brain-derived neurotrophic factor
(BDNF) is known to play a critical role in the survival,
differentiation and synaptic plasticity of mammalian neurons
(see e.g., Cowansage et al., 2010; Edelmann et al., 2014). The
cellular actions of BDNF are mediated mainly through TrkB-
receptors (summarized e.g., in Park and Poo, 2013). In the
adult mammalian brain BDNF is most prominently expressed
in the entorhinal cortex and in the hippocampus (Phillips et al.,
1990; Ferrer et al., 1999; Quartu et al., 1999), brain areas
that are also affected by neuronal loss in AD (Peng et al.,
2005). Furthermore, AD patients have been shown to exhibit
decreased BDNF levels in these regions (Phillips et al., 1991;
Murray et al., 1994; Amoureux et al., 1997), which is mirrored
by reduced blood serum BDNF levels in AD patients (Laske
et al., 2006). In vitro experiments demonstrated that BDNF
exerts several neuroprotective effects by reducing the cytotoxic
effects of Aβ42 (Arancibia et al., 2008) and by stimulating the
non-amyloidogenic pathway, resulting in a reduction of toxic
Aβ species (Scheuner et al., 1996; Fu et al., 2002; Nishitomi
et al., 2006; Thornton et al., 2006; Rohe et al., 2009). In rodent
and primate models of AD it has been shown that acute
application of BDNF protein can partially rescue Aβ42-induced
neurodegenerative changes (Nagahara et al., 2009). Furthermore,
studies in ADmousemodels revealed that activation of the TrkB-
receptor via application of the recently discovered TrkB-receptor
agonist 7,8-Dihydroxyflavone rescued learning and memory
deficits and reduced Aβ levels in the brain (Devi and Ohno, 2012;
Castello et al., 2014; Zhang et al., 2014).
Taken together, several lines of evidence suggest that direct
application of BDNF or activation of TrkB-receptors exert a
protective effect against AD pathology and that the expression
of BDNF seems to be down-regulated in AD patients. However,
the mechanisms explaining how changes in BDNF protein levels
might contribute to the occurrence and severity of AD pathology
are still unknown. To further investigate how altered BDNF
levels might contribute to the progression of AD pathology,
we created a novel mouse model that combines AD pathology
with chronically reduced BDNF levels. We crossed an APP/PS1
mouse model (Radde et al., 2006) with a heterozygous BDNF
knock out (BDNF+/−) mouse (Korte et al., 1995), in which
BDNF protein levels are reduced to roughly 50% of the BDNF
levels observed in wildtype animals (see e.g., Psotta et al.,
2013). We hypothesized that, if endogenous BDNF has a
protective impact against AD pathology, AD-like symptoms
should occur in more severity and/or occur earlier in live history
in this novel mouse model compared to the classical APP/PS1-
mouse line. Therefore, we tested adult (5 months) and aged
(12 months) animals for their cognitive abilities in the novel
object recognition (NOR) task, the two-way active avoidance
paradigm and the Morris water maze (MWM). Also, open field
(OF) and elevated plus maze (EPM) tests were conducted, to
test for possible differences in explorative activity and anxiety
levels. For a more detailed analyis of the neuropathological
characteristics in the investigated mouse lines, amyloid plaque
load in the hippocampus and prefrontal cortex were analyzed by
quantitative immunhistochemistry.
Material and Methods
Animals
Male mice of four different genotypes at the age of 5 and
12 months were used: APP/PS1-mice carrying the human APP
gene locus with the Swedish double mutation KM670/671NL
and L166P mutated human PS1 under control of the Thy1
minigene promoter (Radde et al., 2006); BDNF+/−-mice (Korte
et al., 1995); APP/PS1-BDNF+/−-mice: crossbreeding between
APP/PS1- and BDNF+/−-mice. All mouse lines were bred
on C57BL/6J genetic background (Charles River, Sulzfeld,
Germany). Mice were kept under standard conditions with
2--4 animals per cage in a dark-light cycle of 12 h (light
on at 7:00 a.m.) with food and water ad libitum. The
offsprings of APP/PS1 × BDNF+/− breeding pairs were weaned
between 3--4 weeks of age and maintained in groups of 3--4
animals each. Tail cuts were used for genotyping, according to
previously published polymerase chain reaction (PCR) protocols
for BDNF+/− (Abidin et al., 2008) and APP/PS1-mice (Radde
et al., 2006). All experiments were carried out during the light
phase of the animals. The experiments were in accordance
with the guidelines for the use of animals in experiments
and were approved by the local animal welfare committee
(Landesverwaltungsamt Sachsen-Anhalt, 42502-2-1047UniMD
and 42502-2-1132UniMD).
Behavioral Testing
Open Field (OF)
Exploratory behavior was tested in an OF arena (50 × 50 × 35
cm3). At the beginning of the test individual animals were placed
in the center of the arena were allowed to freely explore the maze
for five minutes. Exploratory behavior (total distance traveled,
time in center) was automatically recorded and analyzed using
a video tracking software (AnyMaze, Stoelting Co., Wood Dale,
IL). For the analysis of exploratory behavior a virtual center area
of 30 × 30 cm2 was defined. The center of the animal body was
defined as tracking point. After the test, animals were returned
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to the home cage. The arena was intensively cleaned after each
animal to prevent odor cues.
Elevated Plus Maze (EPM)
To analyze anxiety-like behavior, an EPM test was performed.
The EPM consisted of two open (5 × 30 cm2) and two closed
(5 × 30 × 15 cm3) arms elevated 40 cm from the floor. At the
beginning of the experiment animals were placed in the center
of the EPM (every animal in the same orientation) and were
allowed to freely explore the maze for five minutes. The center
of the animal body was defined as tracking point. After each
trial the maze was cleaned carefully to prevent odor cues. The
parameters time on the open arms and total distance traveled
were automatically recorded and analyzed (AnyMaze, Stoelting
Co., Wood Dale, IL).
Novel Object Recognition (NOR)
To evaluate short-term object memory abilities, a NOR task was
performed in a rectangular arena (30× 45 cm2). During the first
exposure two identical objects were presented to each individual
animal, which was allowed to explore the objects for 10 min. The
objects and their position in the arena was pseudorandomized
between the different animals. After a 30 min break one of these
objects was replaced by a novel object, again the animals were
allowed to explore the objects for 10 min. An observer blind to
the genotype of the respective animal manually recorded the time
the animals explored each object.
Morris Water Maze (MWM)
Spatial learning performance was tested in the MWM. The
MWM consisted of a circular pool with a diameter of 150 cm
filled with opaque water (22 ± 1◦C) to hide the escape platform.
The platform was placed in the center of one of four quadrants
(target quadrant), which virtually divided the maze. White
curtains with different patterns surrounded the maze and served
as distal visual cues to allow spatial orientation. Experiments were
automatically recorded and analyzed by a video tracking software
(AnyMaze, Stoelting Co., Wood Dale, IL).
The animals were exposed to four training trials (60 s with an
inter-trial-interval of 20 min) per day on four consecutive days.
Each individual was placed in the maze at pseudo-randomized
starting positions facing the wall of the tank. The time the
animals needed to reach the platform (latency) was recorded. 24 h
after the last training trial a probe trial was conducted (60 s),
in which the platform was removed and memory performance
was tested by the time the animals spent in the former target
quadrant.
Two-way Active Avoidance Training (TWAA)
For testing active avoidance behavior an automated shuttle-
box system (TSE Systems, Bad Homburg, Germany) was used.
The apparatus was divided into two compartments (14 × 15.5
× 16 cm3), which were separated by a non-transparent white
Plexiglas wall with an opening to allow access to the other
compartment. Training was conducted on five consecutive days
and started every day with a habituation phase of three minutes,
during which the animals were allowed to freely explore the
shuttle box, followed by 50 trials of CS-UCS pairings. A trial
started with the presentation of a conditioned stimulus (CS;
4.0 kHz tone, 80 dB SPL; max. 5 s), which was immediately
followed by simultaneous presentation of the CS and an
unconditioned stimulus (0.3 mA foot-shock, max. 15 s) and
an inter-trial interval of 20 s. Successful learning was assessed
by counting the number of avoidance responses, which were
recorded automatically. An avoidance response was recorded
when the mouse moved to the opposite compartment during
the initial CS presentation (i.e., within 5 s), but prior to US
onset.
For the described behavioral experiments animals were
assigned to one of two behavioral test batteries: (1) OF, followed
by EPM and after a break of 2 days followed by two-way active
avoidance training (TWAA) (n = 8--10 per genotype and age
group). (2) NOR and after a break of 2 days followed by MWM
(n = 8--12 per genotype and age group).
Immunohistochemistry
To gain more detailed information about neuropathological
characteristics related to ADwe analyzed the amyloid plaque load
in all for genotypes (wildtype, APP/PS1, BDNF+/−, APP/PS1-
BDNF+/−) by quantitative immunohistochemistry. For this
analysis untrained males at the age of 5 and 12 months were
used.
Animals were anesthetized with an intramuscular injection
of a ketamine/xylazine mixture (4 + 1), and perfused with
tyrode buffer followed by 4% paraformaldehyde as fixative.
After perfusion brains were removed and postfixed over night
in 4% paraformaldehyde. Using a vibrating blade microtome
(vibratome, Leica Biosystems, Wetzlar, Germany) brains were
cut into 40 µm slices, washed with phosphate buffered saline
(PBS) and incubated with Goat Serum for 1 h, followed
by incubation with a monoclonal Beta-Amyloid Antibody
(Covance, 1:2000) over night. On the following day, brain
slices were washed, incubated with biotinylated goat anti-mouse
IgG (Millipore, 1:200) for 1 h followed by incubation with
Streptavidin-Biotinylated Horseradish Peroxidase Complex (GE
Healthcare, 1:100) for 1 h. Slices were stained with the 3,3′-
diaminobenzidine (DAB) method and sections were dehydrated,
made transparent and mounted by using conventional methods.
Analysis of amyloid plaque load (plaque density) in the
hippocampus and prefrontal cortex was done by using a
computerized system (Neurolucida, Micro Bright Field, USA) for
the analysis and quantification of microscopic images (Olympus
BX51).
Data Analysis
Statistical analysis was performed using SPSS (version 22.0; SPSS
Inc., Chicago, USA). For the OF and EPM a one-way ANOVA
with genotype as the main factor was applied, followed by a
least significant differences (LSD) post hoc test. For the NOR
a two-way ANOVA with the main factors object and genotype
was performed, followed by a LSD post hoc test. For MWM and
TWAA a two-way repeated measures ANOVA with main factors
day of training and genotype, followed by a LSD post hoc test was
applied. Wildtype mice were defined as control group for all post
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hoc tests. For the analysis of amyloid plaque density a three-way
ANOVA with the main factors age, brain region and genotype
was performed. The level of significance was set at p< 0.05.
Results
Aged but not Adult APP/PS1-mice Show
Reduced Exploratory Behavior in the Open Field
Exploratory behavior was assessed by an open OF test
(Figure 1A). One-way ANOVA revealed no significant
differences in the total distance traveled between the four
genotypes (F3,40 = 2.3, p = 0.09) in five months old animals.
In contrast, for twelve months old animals a significant
difference between the four genotypes could be observed
(F3,37 = 4.5, p = 0.01). A LSD post hoc test revealed reduced
explorative activity in 12 months old APP/PS1-mice compared
to wildtype mice. No significant differences were found for the
BDNF+/−-mice and the APP/PS1-BDNF+/−-mice compared to
wildtype mice.
For the time animals spent in the center of the OF one-way
ANOVA revealed no significant differences between the four
genotypes, neither for 5 nor for 12 months old animals (F’s≤ 2.1;
p’s ≥ 0.1, Figure 1A).
Adult and Aged BDNF+/−- and
APP/PS1-BDNF+/−-mice Display Reduced
Anxiety Levels in the Elevated Plus Maze
Basal anxiety levels were analyzed by an EPM test (Figure 1B). In
five months old animals one-way ANOVA revealed a significant
difference between the four genotypes for the time spent on the
open arm (F3,34 = 4.3, p = 0.01). LSD post hoc test revealed
that BDNF+/−-mice as well as APP/PS1-BDNF+/−-mice spent
significantly more time on the open arms compared to wildtype
mice.
Similarly, a significant difference in anxiety behavior between
the four genotypes was also observed in twelve months old
animals (F3,38 = 7.1, p = 0.001). LSD post hoc test revealed that
APP/PS1-BDNF+/−-mice spent significantly more time on the
open arm compared to wildtype mice.
For explorative behavior (total distance traveled) during the
EPM test one-way ANOVA revealed no significant differences
between the genotypes in five months old animals (F = 2.7,
p = 0.07). However, a significant effect for the factor genotype was
observed in twelve months old animals (F3,38 = 5.7, p = 0.003).
A LSD post hoc test revealed lower exploratory behavior in
APP/PS1-mice compared to the wildtype but no differences for
the BDNF+/−-mice and the APP/PS1-BDNF+/−-mice compared
to wildtype mice.
No Impairment in Short-Term Memory of
BDNF+/−-, APP/PS1- and
APP/PS1/BDNF+/−-mice
In order to analyze the short-term memory abilities of the tested
animals, we applied a NOR task (Figure 1C). During the object
habituation trial there was no difference in the total exploration
time between the four genotypes at any tested age (F’s ≤ 0.6,
FIGURE 1 | (A) Activity (distance moved) and anxiety behavior (time spent in
center region) tested in the Open Field of 5 and 12 months old animals. (B)
Anxiety behavior (time spent in the open arm) in the EPM experiment of 5 and
12 months old animals. (C) Short-term memory tested in the Novel Object
Recognition test of 5 and 12 months old animals. In all diagrams the mean
values + SEM for the four genotypes (WT-, APP/PS1-, BDNF+/−- and
APP/PS1-BDNF+/−-mice) are shown.
p’s≥ 0.6), indicating that the mutations had no impact on object
exploration behavior. After an interval of 30 min one object was
replaced by a novel object. All genotypes at both tested ages
spent significantly more time exploring the novel object than
the familiar object (F’s ≥ 11.6, p’s < 0.005) indicating an intact
short-term memory.
Old APP/PS1- and APP/PS1-BDNF+/−-mice
Show Impaired Acquisition in a Spatial Learning
Task
The spatial learning capacities of the mice were assessed by using
the classical MWM paradigm (Figure 2).
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FIGURE 2 | Spatial learning performance tested by Morris Water
Maze of 5 and 12 months old animals. The left panel depicts the
latency to find the platform during the training phase. The right panel
shows the time the animals spent in the former target vs. the mean time
in the others quadrants during the probe trial performed 24 h after the
last training trial. To rule out that the observed differences in latency are
due to swimming impairments, we analyzed also the swimming speed of
the animals. In all diagrams the mean values (± SEM) of all four
genotypes (WT-, APP/PS1-, BDNF+/−- and APP/PS1-BDNF+/−-mice)
are shown.
As the activity results of the OF and EPM suggested a reduced
explorative activity in 12months old APP/PS1-mice, we analyzed
the swimming speed of the animals in order to rule out motor
impairments that might interfere with latency measurements
(Figure 2). ANOVAs revealed no differences between the tested
genotypes at any tested age (F’s ≤ 0.9, p’s ≥ 0.5), suggesting no
swimming impairments in all transgenic animals at any tested
age. For five months old animals a two-way repeated measure
ANOVA revealed a significant effect of the factor day, indicating
a reduced latency to find the platform during the training
phase in all four genotypes (day: F3,111 = 65.5, p < 0.001). In
contrast, there was neither a significant effect of the factor
genotype nor an interaction between the two factors (genotype:
F3,37 = 0.5, p = 0.71, day × genotype: F9,111 = 0.8; p = 0.63). This
indicates that at this age all genotypes showed a similar learning
performance. The analysis of the probe trial revealed a significant
effect of the factor quadrant, since the animals spent significantly
more time in the target quadrant than in the mean of the other
quadrants (quadrant: F1,74 = 31.1, p < 0.001). However, there
was no effect of genotype and no interaction of these two factors
for the probe trial (genotype: F3,74 = 0.6, p = 0.64; quadrant ×
genotype: F3,74 = 2.3, p = 0.09). For a more detailed analysis of
learning performance during the probe trial the preference for
the target quadrant was tested in each genotype with t-tests. This
approach revealed a reliable memory of the former platform
position for wildtype, BDNF+/−- and APP/PS1-BDNF+/−-mice,
since these lines displayed a significant preference for the target
quadrant but not for the APP/PS1-mice.
At twelve months of age a two-way repeated measures
ANOVA revealed significant effects for the factors day and
genotype as well as a significant interaction between these two
factors (day: F3,120 = 45.7, p < 0.001; genotype: F3,40 = 3.4,
p = 0.03; day × genotype: F9,120 = 2.0, p = 0.04). This indicates a
different learning performance over the training days dependent
on the genotype. LSD post hoc analysis revealed that compared
to wildtype mice APP/PS1- as well as APP/PS1-BDNF+/−-mice
showed significantly longer latencies to reach the platform.
The analysis of the probe trial, revealed a significant effect
for the factor quadrant, but neither a significant effect for the
factor genotype nor an interaction of the two factors (quadrant:
F1,80 = 9.99, p = 0.002; genotype: F3,80 = 0.2, p = 0.91; quadrant
× genotype: F3,80 = 0.7, p = 0.56). Again, for a more detailed
analysis of learning performance during the probe trial the
preference for the target quadrant was tested in each genotype
with t-tests. This revealed a reliable memory of the former
platform position only in wildtype mice, since only these mice
displayed a significant preference for the target quadrant.
Early Onset of Impaired Active Avoidance
Learning in APP/PS1-BDNF+/−-mice
A TWAA test (Figure 3) was employed to investigate negative
feedback learning. At five months of age a two-way repeated
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FIGURE 3 | Learning performance in a Two Way Active
Avoidance task (Shuttle Box) in 5 and 12 months old animals.
Diagrams show mean values (± SEM) of the number of avoidance
reactions (correct responses) over the five training days
of all four genotypes (WT-, APP/PS1-, BDNF+/−- and
APP/PS1-BDNF+/−-mice).
measures ANOVA revealed a significant effect of the factor day,
indicating an increase in learning performance over the five
training days for all genotypes (F4,120 = 12.7, p < 0.001). A trend
for the factor genotype (F3,30 = 2.6, p = 0.068) and a significant
interaction between the factors day and genotype was found
(F12,120 = 2.4, p = 0.03), indicating differences in avoidance
learning between the four genotypes over the training period. A
LSD post hoc test revealed that only APP/PS1-BDNF+/−-mice
showed significantly less avoidance responses compared to
wildtype mice indicating impaired ability to learn this particular
task and being in accordance with the hypothesis that additional
reduction of BDNF can aggravate the memory impairment of
APP/PS1-mice.
In twelve months old animals two-way repeated measures
ANOVA revealed a significant effect for the factor day, indicating
an increase in learning performance over the five training
days ( F4,144 = 16.4, p < 0.001). Additionally, a significant
effect was found for the factor genotype (genotype: F3,36 = 4.1,
p = 0.01), indicating different learning performance between
the four genotypes. No significant effect was found for an
interaction between the factors day and genotype (day ×
genotype: F12,144 = 2.1, p = 0.06). LSD post hoc test revealed
that APP/PS1- as well as APP/PS1-BDNF+/−-mice showed
significantly fewer avoidance responses compared to wildtype
mice indicating that at this age a reduced learning performance
of APP/PS1-mice is already detectable in the absence of an
additional reduction of BDNF.
APP/PS1- as well as APP/PS1-BDNF+/−-mice
show Higher Amyloid Plaque Density in the
mPFC than in the Hippocampus
Quantitative immunohistochemistry (Figure 4) was performed
to estimate the amyloid plaque load in the mPFC and
hippocampus of the analyzed genotypes. At first it became
apparent that no amyloid plaques could be detected in wildtype
and BDNF+/−-mice. Therefore, quantitative comparisons were
only performed between APP/PS1- and APP/PS1-BDNF+/−-
mice. Three-way ANOVA revealded a significant effect only for
the factor brain region, (F1,40 = 99.772, p < 0.001), indicating
a higher amyloid plaque density in the mPFC compared to
the hippocampus. We found no effect for the factors age and
genotype and no interactions, which indicates that there is
no age-dependent increase of amyloid plaque densities and
also a comparable amyloid plaque load in the APP/PS1- and
APP/PS1-BDNF+/−-mice.
Discussion
Since there is evidence for an association between altered
BDNF signaling and the occurrence and/or intensity of AD
pathology, the aim of the present study was to combine
these two factors in a novel animal model to study the
impact of chronically reduced endogenous BDNF levels on
the development of AD pathology in vivo. By using this
novel mouse model we could show, that the reduction of
endogenous BDNF within the APP/PS1-mouse model causes an
accelerated onset of learning impairments in a two-way active
avoidance task but not in spatial learning in the MWM. Also
short term memory for object recognition remained unaffected
in APP/PS1-BDNF+/−-mice. Quantitative analysis of plaque
pathology in the two AD mouse lines revealed no differences
between the APP/PS1- and APP/PS1-BDNF+/−-mice and also
no age-dependent increase between 5 and 12 months of age.
However, for both ADmouse lines we found that amyloid plaque
density was significantly higher in the mPFC compared to the
hippocampus.
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FIGURE 4 | Quantitative analysis of amyloid plaque density in the mPFC
(A) and hippocampus (B) in 5 and 12 months old animals. Diagrams show
mean values (+ SEM) of amyloid plaque desnityfor the two AD genotypes
(APP/PS1- and APP/PS1-BDNF+/−-mice).
Our working hypothesis claimed that BDNF deficiency
should accelerate the onset of cognitive impairment and amplify
the cognitive deficits displayed by the APP/PS1-mice. As
predicted, APP/PS1-BDNF+/−-mice showed an earlier onset
of impairments in active avoidance learning compared to
APP/PS1- and BDNF+/− -mice. At five months of age, avoidance
learning was only impaired in APP/PS1-BDNF+/−-mice and
not yet detectable in APP/PS1- or BDNF+/− -mice, whereas
at twelve months of age APP/PS1- and APP/PS1-BDNF+/−-
mice displayed significant learning deficits compared to wildtype
animals. Previous studies testing APP/PS1-mice reported similar
age-dependent deficits in avoidance learning in 9 months old
mice and in eye blink conditioning at the age of twelve months,
which were not yet detectable in threemonth old animals (Gruart
et al., 2008; Lok et al., 2013). Interestingly, no study has tested
BDNF+/−-mice in the TWAA paradigm so far, even though this
task is known to induce BDNF protein expression in several
brain areas (Ulloor and Datta, 2005). Even though 12 months old
BDNF+/−-mice did not perform significantly worse than their
wildtype littermates, our data still show a strong trend to an
impaired learning performance in these animals at this age. This
observation of a probable age-dependent learning decline would
be in line with other studies reporting age-dependent learning
deficits for BDNF+/−-mice in different learning paradigms. For
example, a deficit in fear extinction learning was observed in
7 but not 2 months old BDNF+/−-mice (Psotta et al., 2013)
and BDNF+/−-mice exhibit a deficit in amygdala-dependent
fear learning, when the animals are older than 3 months of
age (Endres and Lessmann, 2012). Together these findings
suggest that different learning paradigms, depending on distinct
brain areas, all suffer from BDNF deficiency only at later
ages.
Importantly, the observed age-dependent decline in the
BDNF+/−-mice seems to appear later and to a weaker
extent than in the APP/PS1- or APP/PS1-BDNF+/−-
mice, suggesting that the observed accelerated onset of
impaired TWAA learning in the young triple transgenic
animals is rather due to an accelerated AD-like pathology
in combination with chronically reduced BDNF protein
levels than simply due to the chronic BDNF reduction
alone.
Importantly, for the investigated basal behavioral parameters
we didn’t observe any changes of explorative activity and
no obvious motoric deficits in the APP/PS1-BDNF+/−-mice.
In contrast, our EPM data indicate a low anxiety phenotype
in the triple mutants. However, it has to be pointed out
that this finding was specific for the EPM, no signs of
enhanced anxiety-like behavior could be observed in the OF.
Taken together, it appears unlikely that the observed learning
deficits are due to alterations in basal explorative activity
of motor deficts but we cannot completely rule out that
the reduced anxiety levels may contribute to the observed
learning impairments in the TWAA paradigm. However, this
appears unlikely since other studies have shown that low
anxiety rats as defined by an enhanced number of entries
into the open arms of an EPM performed better in a two-
way active avoidance task than high anxiety rats, that showed
reduced entries into the open arms of an EPM (Ho et al.,
2002).
In contrast to the findings in our new triple mutant
mouse model, we found reduced locomotor activity in the
12 months old APP/PS1-mice in the OF as well as in the
EPM tests. According to these results one could argue that the
BDNF deletion in APP/PS1 mice restored to normal levels of
locomotor or exploratory behavior in the APP/PS1-BDNF+/−-
mice.
However, in the NOR task we didn’t observe any signs
of reduced motor activity and explorative behavior in the
APP/PS1-mice compared to the other tested animals. Also,
exploratory and motor behavior appeared to be normal
during MWM, since swimming speed wasn’t reduced in
APP/PS1-mice and the latency to find the platform was
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comparable to the wildtype animals throughout the whole
training trials, especially during the first trials that reflect more
general locomotor than learning abilities (Figure 3). Thus,
our findings, which are supported by previous observations
(Radde et al., 2006; Lo et al., 2013a), suggest that there is no
general deficit in motor and explorative behavior in APP/PS1-
mice.
Also in the MWM paradigm, we observed age-dependent
learning deficits. However, in contrast to TWAA learning
these learning deficits occurred to a different extent in
all tested transgenic animals. While training performance
(acquisition) was fully intact in 5 months old animals,
the APP/PS1- as well as the APP/PS1-BDNF+/−-mice
showed significantly reduced training performances at
the age of 12 months, thereby the APP/PS1-BDNF+/−-
mice displayed the worst performance since they showed
the highest latencies during the training phase at that
age.
For the spatial memory tested in the probe trial in 5
months old animals a reduced learning performance was
observed in APP/PS1-mice but not in the other genotypes.
However, this finding in the APP/PS1-mice does not reflect
a completely impaired memory, since these animals still
exhibited a strong tendency towards spending more time in
the previous target quadrant (p = 0.08). At 12 months of
age all tested mutant mouse lines, the BDNF+/−-mice, the
APP/PS1-mice as well as the triple mutant APP/PS1-BDNF+/−
showed an impaired performance in the probe trial when
compared to the wildtype animals. But again, there was no
complete memory blockade since all animals still showed a
trend towards spending more time in the previous target
quadrant.
In general, these findings are in line with other studies
demonstrating age-dependent spatial learning deficits in
APP/PS1-mice occurring around 8/9 months (Radde et al.,
2006; Lo et al., 2013a,b), as well as in BDNF+/−-mice,
occurring around 10--12 months (Linnarsson et al., 1997;
Rantamäki et al., 2013). Interestingly, another study using a
similar mouse model reported an aggravated AD pathology
in the MWM by chronic BDNF reduction (Rantamäki
et al., 2013). However, a direct comparison between the
two mouse models is difficult since we used a different AD
mouse model harboring different APP and PS1 mutations
under control of a different promoter, resulting probably in
different expression patterns of Aβ and subsequent AD-like
pathology.
The quantification of amyloid plaque density in the
two AD mouse models revealed no differences between
the APP/PS1-mouse and our newly created APP/PS1-
BDNF+/−-mouse and also no age-dependent differences
(5 vs. 12 months). This finding indicates that the amyloid
plaque pathology in our new mouse model was not directly
affected by the reduced BDNF level, a result that is in line
with findings described in the study of Rantamäki et al.
(2013).
However, our findings revealed for both analyzed AD mouse
models that the amyloid plaque load was higher in the mPFC
compared to the hippocampus. These results are comparable
to findings of previous studies showing that the classical
APP/PS1-mice exhibits a higher (approx. three fold) plaque
pathology in the cortex compared to the hippocampus (Radde
et al., 2006; Scholtzova et al., 2008; Gengler et al., 2010). In
addition it was shown that the onset of plaque pathology
occurs later in the hippocampus than in the cortex (Radde
et al., 2006). These regional differences in amyloid pathology
might explain our finding of an aggravated learning deficit
in the TWAA task but not in spatial learning, since these
different learning tasks rely on the recruitment of different
neuronal networks. Whereas the spatial MWM learning relies
mainly on the basal ganglia and hippocampal function (Morris
et al., 1982; Cho et al., 1999; Devan and White, 1999; Barry
and Commins, 2011), the more complex TWAA learning
requires besides several limbic structures (Cain and LeDoux,
2008; Choi et al., 2010) also network activity of higher
cortical areas (Martinez et al., 2013; Moscarello and LeDoux,
2013).
Finally, major dysfunctions for short-term memory abilities
were neither observed in our novel triple mutant, nor in the
two respective single transgenic mouse lines (i.e., BDNF+/− and
APP/PS1), regardless of the age of the animals. This finding is
in line with other observations indicating that BDNF signaling
is required for long-term but not short-term object memory
(Seoane et al., 2011; Callaghan and Kelly, 2012). However,
this speculation has to be assessed in future experimental
approaches applying specific long-term and short-term memory
tasks.
In conclusion, we could demonstrate that according to our
hypothesis the chronic reduction of BDNF levels in our novel
AD-mouse model indeed accelerated the onset of learning
deficits in two way active avoidance learning. However, we
could identify this acceleration only for TWAA learning but not
for spatial learning in the MWM and for short-term memory
in an object recognition task in the analyzed age groups.
Overall, the creation of the triple transgenic mouse model was
a further step to study the interrelation of BDNF and Aβ
pathology in vivo. As the effects of chronic BDNF reduction
vary between learning tasks requiring different complex brain
networks this novel mouse model provides an interesting
tool to further understand how differently regulated Aβ and
BDNF expression relate to cognitive declines in AD pathology.
Furthermore, this mouse model might be a promising model
system to test BDNF-related treatment strategies against AD
pathology. Thus, the APP/PS1-BDNF+/−-mouse model created
in this study provides new opportunities to investigate the
underlying molecular and cellular mechanisms of AD in more
detail.
Acknowledgments
The authors want to thank Colette Obst and Evelyn Friedl
for excellent technical support. This study was funded by the
federal state of Saxony-Anhalt and the ‘‘European Regional
Development Fund’’ (ERDF 2007--2013), Project: Center for
Behavioral Brain Sciences (CBBS).
Frontiers in Behavioral Neuroscience | www.frontiersin.org 8 March 2015 | Volume 9 | Article 58
Psotta et al. BDNF in Alzheimer’s disease
References
Abidin, I., Eysel, U. T., Lessmann, V., and Mittmann, T. (2008). Impaired
GABAergic inhibition in the visual cortex of brain-derived neurotrophic
factor heterozygous knockout mice. J. Physiol. 586, 1885--1901. doi: 10.1113/
jphysiol.2007.148627
Amoureux, M. C., Van, G. D., Herrero, M. T., Dom, R., Colpaert, F. C., and
Pauwels, P. J. (1997). Regulation of metallothionein-III (GIF) mRNA in
the brain of patients with Alzheimer disease is not impaired. Mol. Chem.
Neuropathol. 32, 101--121. doi: 10.1007/bf02815170
Arancibia, S., Silhol, M., Moulière, F., Meffre, J., Höllinger, I., Maurice, T., et al.
(2008). Protective effect of BDNF against beta-amyloid induced neurotoxicity
in vitro and in vivo in rats.Neurobiol. Dis. 31, 316--326. doi: 10.1016/j.nbd.2008.
05.012
Barry, D. N., and Commins, S. (2011). Imaging spatial learning in the brain using
immediate early genes: insights, opportunities and limitations. Rev. Neurosci.
22, 131--142. doi: 10.1515/RNS.2011.019
Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer’s disease. Lancet
368, 387--403. doi: 10.1016/S0140-6736(06)69113-7
Cain, C. K., and LeDoux, J. E. (2008). Brain mechanisms of Pavlovian and
instrumental aversive conditioning. Handb. Behav. Neurosci. 17, 103--124.
doi: 10.1016/s1569-7339(07)00007-0
Callaghan, C. K., and Kelly, A. M. (2012). Differential BDNF signaling in dentate
gyrus and perirhinal cortex during consolidation of recognition memory in the
rat. Hippocampus 22, 2127--2135. doi: 10.1002/hipo.22033
Castello, N. A., Nguyen, M. H., Tran, J. D., Cheng, D., Green, K. N., and
LaFerla, F. M. (2014). 7,8-Dihydroxyflavone, a small molecule TrkB agonist,
improves spatial memory and increases thin spine density in a mouse model of
Alzheimer disease-like neuronal loss. PLoS One 9:e91453. doi: 10.1371/journal.
pone.0091453
Cho, Y. H., Friedman, E., and Silva, A. J. (1999). Ibotenate lesions of the
hippocampus impair spatial learning but not contextual fear conditioning in
mice. Behav. Brain Res. 98, 77--87. doi: 10.1016/s0166-4328(98)00054-0
Choi, J.-S., Cain, C. K., and LeDoux, J. E. (2010). The role of amygdala nuclei in the
expression of auditory signaled two-way active avoidance in rats. Learn. Mem.
17, 139--147. doi: 10.1101/lm.1676610
Cowansage, K. K., LeDoux, J. E., and Monfils, M. H. (2010). Brain-derived
neurotrophic factor: a dynamic gate-keeper of neural plasticity. Curr. Mol.
Pharmacol. 3, 12--29. doi: 10.2174/1874467211003010012
Devan, B. D., and White, N. M. (1999). Parallel information processing in the
dorsal striatum: relation to hippocampal function. J. Neurosci. 19, 2789--
2798.
Devi, L., and Ohno, M. (2012). 7,8-dihydroxyflavone, a small-molecule TrkB
agonist, reverses memory deficits and BACE1 elevation in a mouse model of
Alzheimer’s disease. Neuropsychopharmacology 37, 434--444. doi: 10.1038/npp.
2011.191
Edelmann, E., Lessmann, V., and Brigadski, T. (2014). Pre- and postsynaptic
twists in BDNF secretion and action in synaptic plasticity. Neuropharmacology
76(Pt. C), 610--627. doi: 10.1016/j.neuropharm.2013.05.043
Endres, T., and Lessmann, V. (2012). Age-dependent deficits in fear learning
in heterozygous BDNF knock-out mice. Learn. Mem. 19, 561--570. doi: 10.
1101/lm.028068.112
Ferrer, I., Marin, C., Rey, M. J., Ribalta, T., Goutan, E., Blanco, R., et al. (1999).
BDNF and full-length and truncated TrkB expression in Alzheimer disease.
Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 58, 729--739.
doi: 10.1097/00005072-199907000-00007
Fu, W., Lu, C., and Mattson, M. P. (2002). Telomerase mediates the cell
survival-promoting actions of brain-derived neurotrophic factor and secreted
amyloid precursor protein in developing hippocampal neurons. J. Neurosci. 22,
10710--10719.
Gengler, S., Hamilton, A., and Hölscher, C. (2010). Synaptic plasticity in the
hippocampus of a APP/PS1 mouse model of Alzheimer’s disease is impaired
in old but not young mice. PLoS One 5:e9764. doi: 10.1371/journal.pone.000
9764
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani,
L., et al. (1991). Segregation of a missense mutation in the amyloid precursor
protein gene with familial Alzheimer’s disease. Nature 349, 704--706. doi: 10.
1038/349704a0
Gruart, A., López-Ramos, J. C., Muñoz, M. D., and Delgado-García, J. M. (2008).
Aged wild-type and APP, PS1 and APP+PS1 mice present similar deficits
in associative learning and synaptic plasticity independent of amyloid load.
Neurobiol. Dis. 30, 439--450. doi: 10.1016/j.nbd.2008.03.001
Hardy, J. A., and Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256, 184--185. doi: 10.1126/science.1566067
Ho, Y. J., Eichendorff, J., and Schwarting, R. K. (2002). Individual response profiles
of male Wistar rats in animal models for anxiety and depression. Behav. Brain
Res. 136, 1--12. doi: 10.1016/s0166-4328(02)00089-x
Kawas, C. H., and Corrada, M. M. (2006). Alzheimer’s and dementia in the
oldest-old: a century of challenges. Curr. Alzheimer Res. 3, 411--419. doi: 10.
2174/156720506779025233
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., and Bonhoeffer, T. (1995).
Hippocampal long-term potentiation is impaired in mice lacking brain-derived
neurotrophic factor. Proc. Natl. Acad. Sci. U S A 92, 8856--8860. doi: 10.
1073/pnas.92.19.8856
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Schott, K., Langer, H.,
et al. (2006). Decreased brain-derived neurotrophic factor (BDNF)- and
β-thromboglobulin (β-TG)- blood levels in Alzheimer’s disease. Thromb.
Haemost. 96, 102--103. doi: 10.1160/th06-03-0173
Linnarsson, S., Björklund, A., and Ernfors, P. (1997). Learning deficit in BDNF
mutant mice. Eur. J. Neurosci. 9, 2581--2587. doi: 10.1111/j.1460-9568.1997.
tb01687.x
Lo, A. C., Callaerts-Vegh, Z., Nunes, A. F., Rodrigues, C. M., and D’Hooge,
R. (2013a). Tauroursodeoxycholic acid (TUDCA) supplementation prevents
cognitive impairment and amyloid deposition in APP/PS1mice.Neurobiol. Dis.
50, 21--29. doi: 10.1016/j.nbd.2012.09.003
Lo, A. C., Tesseur, I., Scopes, D. I., Nerou, E., Callaerts-Vegh, Z., Vermaercke,
B., et al. (2013b). Dose-dependent improvements in learning and memory
deficits in APPPS1--21 transgenic mice treated with the orally active Abeta
toxicity inhibitor SEN1500. Neuropharmacology 75C, 458--466. doi: 10.1016/j.
neuropharm.2013.08.030
Lok, K., Zhao, H., Shen, H., Wang, Z., Gao, X., Zhao, W., et al. (2013).
Characterization of the APP/PS1 mouse model of Alzheimer’s disease in
senescence accelerated background. Neurosci. Lett. 557, 84--89. doi: 10.1016/j.
neulet.2013.10.051
Martinez, R. C., Gupta, N., Lázaro-Muñoz, G., Sears, R. M., Kim, S., Moscarello,
J. M., et al. (2013). Active vs. reactive threat responding is associated with
differential c-Fos expression in specific regions of amygdala and prefrontal
cortex. Learn. Mem. 18, 446--452. doi: 10.1101/lm.031047.113
Morris, R. G., Garrud, P., Rawlins, J. N., and O’Keefe, J. (1982). Place navigation
impaired in rats with hippocampal lesions. Nature 297, 681--683. doi: 10.
1038/297681a0
Moscarello, J. M., and LeDoux, J. E. (2013). Active avoidance learning requires
prefrontal suppression of amygdala-mediated defensivereactions. J. Neurosci.
27, 3815--3823. doi: 10.1523/JNEUROSCI.2596-12.2013
Murray, K. D., Gall, C. M., Jones, E. G., and Isackson, P. J. (1994).
Differential regulation of brain-derived neurotrophic factor and type II
calcium/calmodulin-dependent protein kinase messenger RNA expression
in Alzheimer’s disease. Neuroscience 60, 37--48. doi: 10.1016/0306-4522(94)
90202-x
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked,
G. M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic
factor in rodent and primate models of Alzheimer’s disease. Nat. Med. 15,
331--337. doi: 10.1038/nm.1912
Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A. J., Maeda, M., Hirata-Fukae,
C., et al. (2006). BACE1 inhibition reduces endogenous Abeta and alters APP
processing in wild-type mice. J. Neurochem. 99, 1555--1563. doi: 10.1111/j.
1471-4159.2006.04178.x
Park, H., and Poo, M. M. (2013). Neurotrophin regulation of neural circuit
development and function. Nat. Rev. Neurosci. 14, 7--23. doi: 10.1038/nrn3379
Peng, S., Wuu, J., Mufson, E. J., and Fahnestock, M. (2005). Precursor form
of brain-derived neurotrophic factor and mature brain-derived neurotrophic
factor are decreased in the pre-clinical stages of Alzheimer’s disease. J.
Neurochem. 93, 1412--1421. doi: 10.1111/j.1471-4159.2005.03135.x
Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., and
Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of
individuals with Alzheimer’s disease. Neuron 7, 695--702. doi: 10.1016/0896-
6273(91)90273-3
Frontiers in Behavioral Neuroscience | www.frontiersin.org 9 March 2015 | Volume 9 | Article 58
Psotta et al. BDNF in Alzheimer’s disease
Phillips, H. S., Hains, J. M., Laramee, G. R., Rosenthal, A., and Winslow, J. W.
(1990). Widespread expression of BDNF but not NT3 by target areas of
basal forebrain cholinergic neurons. Science 250, 290--294. doi: 10.1126/science.
1688328
Psotta, L., Lessmann, V., and Endres, T. (2013). Impaired fear extinction learning
in adult heterozygous BDNF knock-out mice. Neurobiol. Learn. Mem. 103,
34--38. doi: 10.1016/j.nlm.2013.03.003
Quartu, M., Lai, M. L., and Del Fiacco, M. (1999). Neurotrophin-like
immunoreactivity in the human hippocampal formation. Brain Res. Bull. 48,
375--382. doi: 10.1016/s0361-9230(99)00009-x
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L.,
et al. (2006). Aβ42-driven cerebral amyloidosis in transgenic mice reveals early
and robust pathology. EMBO Rep. 7, 940--946. doi: 10.1038/sj.embor.7400784
Rantamäki, T., Kemppainen, S., Autio, H., Stavén, S., Koivisto, H., Kojima, M.,
et al. (2013). The impact of Bdnf gene deficiency to the memory impairment
and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer’s disease.
PLoS One 8:e68722. doi: 10.1371/journal.pone.0068722
Rohe, M., Synowitz, M., Glass, R., Paul, S. M., Nykjaer, A., and Willnow, T. E.
(2009). Brain-derived neurotrophic factor reduces amyloidogenic processing
through control of SORLA gene expression. J. Neurosci. 29, 15472--15478.
doi: 10.1523/JNEUROSCI.3960-09.2009
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al.
(1996). Secreted amyloid beta-protein similar to that in the senile plaques of
Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP
mutations linked to familial Alzheimer’s disease.Nat. Med. 2, 864--870. doi: 10.
1038/nm0896-864
Scholtzova, H., Wadghiri, Y. Z., Douadi, M., Sigurdsson, E. M., Li, Y. S.,
Quartermain, D., et al. (2008). Memantine leads to behavioral improvement
and amyloid reduction in Alzhei-mer’s-disease-model transgenic mice shown
as by micromagnetic resonance imaging. J. Neurosci. Res. 86, 2784--2791.
doi: 10.1002/jnr.21713
Seoane, A., Tinsley, C. J., and Brown, M. W. (2011). Interfering with perirhinal
brain-derived neurotrophic factor expression impairs recognition memory in
rats. Hippocampus 21, 121--126. doi: 10.1002/hipo.20763
Theuns, J., Marjaux, E., Vandenbulcke, M., Van Laere, K., Kumar-Singh, S.,
Bormans, G., et al. (2006). Alzheimer dementia caused by a novel mutation
located in the APP C-terminal intracytosolic fragment. Hum. Mutat. 27,
888--896. doi: 10.1002/humu.20402
Thornton, E., Vink, R., Blumbergs, P. C., and Van Den Heuvel, C. (2006).
Soluble amyloid precursor protein alpha reduces neuronal injury and improves
functional outcome following diffuse traumatic brain injury in rats. Brain Res.
1094, 38--46. doi: 10.1016/j.brainres.2006.03.107
Ulloor, J., and Datta, S. (2005). Spatio-temporal activation of cyclic AMP
response element-binding protein, activity-regulated cytoskeletal-associated
protein and brain-derived nerve growth factor: a mechanism for pontine-wave
generator activation-dependent two-way active-avoidance memory processing
in the rat. J. Neurochem. 95, 418--428. doi: 10.1111/j.1471-4159.2005.
03378.x
Walker, E. S., Martinez, M., Brunkan, A. L., and Goate, A. (2005). Presenilin 2
familial Alzheimer’s disease mutations result in partial loss of function and
dramatic changes in Abeta 42/40 ratios. J. Neurochem. 92, 294--301. doi: 10.
1111/j.1471-4159.2004.02858.x
Zhang, Z., Liu, X., Schroeder, J. P., Chan, C. B., Song, M., Yu, S. P., et al. (2014).
7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse
model of Alzheimer’s disease. Neuropsychopharmacology 39, 638--650. doi: 10.
1038/npp.2013.243
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Psotta, Rockahr, Gruss, Kirches, Braun, Lessmann, Bock and
Endres. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution and reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 10 March 2015 | Volume 9 | Article 58
